Drug Pricing
Featured Topics
Lead story
Other featured articles
-
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.
Posted in -
Schaeffer Co-Director Testifies on PBMs at Senate Congressional Hearing
Erin Trish was part of a panel of witnesses called to testify before the Committee on Commerce, Science and Transportation.
Posted in -
Testimony on Bringing Transparency and Accountability to Pharmacy Benefit Managers Â
Erin Trish spoke at the Senate Committee on Commerce, Science, & Transportation on February 16, 2023 about the complex and influential role that pharmacy benefit managers (PBMs) play in the pharmaceutical distribution system.
Posted in -
The Impact of Direct-to-Consumer Advertising on Outpatient Care Utilization
Neeraj Sood and colleagues inform the debate about direct-to-consumer advertising by analyzing the effects of ads on office visits and treatment courses for five common chronic conditions.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug Pricing
Our Work In Drug Pricing
-
The Urgent Need for a New Generation of Antibiotics
Health policy experts discuss how to ensure the development of new antimicrobials to replace antibiotics and other critical medications that are beginning to lose their effectiveness.
-
Shame Won’t Solve America’s Obesity Crisis: How Congress Can Help
If saving lives is the objective, then logic, clinical evidence and compassion dictate that Medicare should pay for preventing and treating obesity, starting now.
-
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
Categorized in Evidence Base -
During the Height of the Opioid Epidemic, the Out-of-Pocket Price of Naloxone Increased by Over 500%
A jump in the out-of-pocket price of naloxone has likely made the lifesaving drug too expensive for most uninsured Americans.
Categorized in Evidence Base -
Drugmakers Aren’t Driving Inflation. Price Controls Would Hinder Medical Progress
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
-
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.